Figure 2From: Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cellsEffects of alemtuzumab on total nucleated cells and CD34+ cells. 100,000 CD34+ cells were cultured in 2 ml StemSpan™ SFEM Medium supplemented with 10% of healthy human serum, 50 ng/ml of stem cell factor, TPO and Flt3 Ligand. 10 μg/ml of alemtuzumab was added to test the alemtuzumab's effects on HSC expansion. Cultures were maintained at 37°C with humidified air containing 5% CO2 for 5 weeks. A small fraction of the cultures were harvested at day 7, 14 to test absolute total nucleated cell expansion. (A), CD34+ cell percentages (B), Absolute CD34+ cell numbers in control and alemtuzumab treatment groups. Results are representative of 6 separate experiments from different fresh cord blood samples.Back to article page